Tag: OSX
Osteopore and Singular Health collaborate on AI-powered cranial implant design process
Bone healing biotech Osteopore (ASX: OSX) has inked a deal with Singular Health Group (ASX: SHG) for a comparative study between Osteopore’s existing cranial implant design process and a new artificia...
Osteopore’s regenerative bone implants to be further developed under new clinical trials
Osteopore (ASX: OSX) will further refine its next generation scaffolds after agreeing to sponsor two clinical trials for its regenerative implants in Australia.
Under a new agreement, world recogni...
Osteopore improves margins ahead of forecast increase in elective surgeries
Medical technology company Osteopore (ASX: OSX) says the “robust capital position” it ended the June quarter in will enable it to take advantage of an expected increase in elective surgeries.
The A...
Osteopore receives European certification for expanded line of bone healing products
Australian-Singaporean medical technology company Osteopore (ASX: OSX) has received European CE Mark certification for seven new designs in its range of 3D-printed biomimetic, bioresorbable craniofaci...
Osteopore collars European patent for next generation bone regenerative implant technology
Osteopore’s (ASX: OSX) bone healing technology has reached another milestone after the European Patent Office granted a patent for the company’s next generation of regenerative implants.
The patent...
Osteopore reports consistent revenue growth and upscales global distribution
Osteopore (ASX: OSX) has updated the market with strong company performance figures, declaring it recorded four straight quarters of revenue growth last year including a $429,700 result in the 2020 fo...
Osteopore signs deal to distribute medical implant products through German and Austrian markets
Bone healing biotech Osteopore (ASX: OSX) has signed an exclusive two-year agreement with medical device distributor MTG Medizintechnik Göhl to promote and sell its products in Germany and Austria.
...
Osteopore adds former ResMed executive Carl Runde to its board
Osteopore (ASX: OSX) has boosted its board with the appointment of highly experienced and former ResMed (ASX: RMD) executive Carl Runde to the role of chief financial officer.
According to Osteopor...
Osteopore inks Australia and NZ distribution deal for bone healing scaffolds
Bone healing biotech company Osteopore (ASX: OSX) has signed an exclusive deal with Australian-owned LMT Surgical to promote and sell its 3D-printed medical products within the Australian and New Zeal...
Osteopore shrugs off COVID-19 to report 40% revenue growth
Medical technology company Osteopore (ASX: OSX) revealed it experienced “encouraging sales growth” with quarterly revenue growing to over $408,000, despite challenges posed by COVID-19.
The feat re...
Osteopore looks to expand its range of 3D-printed bioresorbable implants
Medical technology company Osteopore (ASX: OSX) has taken a step towards expanding its range of 3D-printed bioresorbable products by signing a research collaboration agreement with the National Univer...
Investors back Osteopore’s expansion plans in $8.5m placement
Advanced bone healing company Osteopore (ASX: OSX) has secured further investor support for its regeneration technology, with the company revealing it had received binding commitments for a $8.5 milli...
Osteopore to secure bone implant technology from QUT for use in orthopaedic surgeries
Bone healing company Osteopore (ASX: OSX) has signed an exclusive option to licence novel 3D-printed modular bone implant technology being developed by Queensland University of Technology for use in o...
Osteopore signs first US distribution deal for 3D-printed craniofacial scaffolds
Bone healing biotech company Osteopore (ASX: OSX) has secured an agreement with American cranial bone fixation specialist Bioplate Inc to promote and sell Osteopore products into the US market.
It ...
Securing best distributor is key to commercialisation in the medical field
A company can create a product that has the ability to change the world, but its commercial success and failure often hinges on how the product enters the market – particularly for complex products li...
COVID-19 prompts increased shift towards 3D printed medical material
With 3D printed material becoming increasingly common in the medical field, the onset of COVID-19 has sparked even further demand for materials made in this revolutionary fashion.
Low supplies and ...
Osteopore receives TGA approval for 3D-printed medical scaffolds in Australia
Osteopore (ASX: OSX) is now be able to make its 3D-printed medical scaffolds widely available across Australia after its three craniofacial products were approved by the Therapeutic Goods Administrati...
Osteopore continues sales momentum despite COVID-19 climate
Biotech company Osteopore (ASX: OSX) is continuing to see strong sales of its 3D-printed ‘bone healing’ implants as its Singaporean manufacturing facility remains fully operational amid COVID-19 conta...
Osteopore boosts revenue, plans to break into Chinese and US markets
Bone healing biotech company Osteopore (ASX: OSX) has posted strong revenue growth since its ASX debut, eyeing China and the US as the next markets for its regenerative technology.
The Austra...
Osteopore makes ASX debut, plans to become leading producer of 3D-printed implants to promote bone regeneration
Medical technology company Osteopore (ASX: OSX) has made its ASX debut with a $20.2 million market capitalisation following a successful initial public offering which closed early due to strong invest...
